Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205660 · ClinicalTrials.gov registry record · Phase 4
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
A Phase 4 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT00205660 is a Phase 4 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 51 participants.
The verdict
NCT00205660, a Phase 4 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the metabolic effects of 12 weeks of aripiprazole treatment following chronic pretreatment with olanzapine, quetiapine, risperidone or ziprasidone. We hypothesize that switching to aripiprazole treatment will induce improvements in total body adiposity, inflammation (e.g., high sensitivity C-reactive protein \[hsCRP\]), glucose metabolism (e.g., insulin sensitivity) and lipid metabolism (e.g., fasting plasma triglyceride), in comparison to chronic pretreatment with olanzapine, risperidone and quetiapine.
Interventions
- OTHER Stayers
- OTHER Switchers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205660
The ClinicalTrials.gov registry entry for NCT00205660 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stayers is the first listed.
NCT00205660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205660 about?
NCT00205660 is a clinical study titled "Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole". This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the metabolic effects of 12 weeks of aripiprazole treatment following chronic pret...
What is the current status of trial NCT00205660?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2005-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00205660?
The interventions under investigation include: Stayers (OTHER), Switchers (OTHER).
Who is sponsoring clinical trial NCT00205660?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.